SCHEMBL4726068

SCHEMBL4726068

CS(=O)(=O)CCOCc1csc(NC(=O)NCc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 16/20 0.44
ROCK2 O75116 15/20 0.44
AKT1 P31749 2/20 0.44
GSK3B P49841 2/20 0.44
LIMK1 P53667 2/20 0.44
CDC42BPA Q5VT25 2/20 0.44
SGK1 O00141 1/20 0.44
TNK2 Q07912 1/20 0.44
DMPK Q09013 1/20 0.44
MYLK Q15746 1/20 0.44
TSHR P16473 1/20 0.41
TRPV1 Q8NER1 3/20 0.41
AURKA O14965 1/20 0.40
DYRK3 O43781 1/20 0.40
PRKD3 O94806 1/20 0.40
PRKCG P05129 1/20 0.40
PRKACA P17612 1/20 0.40
RPS6KB1 P23443 1/20 0.40
MARK3 P27448 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777329 0.89 ROCK1 (0.43) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4727612 0.88 ROCK1 (0.55) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4780046 0.88 TSHR (0.46) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4777271 0.88 ROCK1 (0.48) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4725694 0.88 ROCK1 (0.44) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4726471 0.87 ROCK1 (0.47) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4725491 0.87 ROCK1 (0.47) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4777278 0.87 ROCK1 (0.44) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4778546 0.87 ROCK1 (0.44) ROCK1ROCK2AKT1GSK3BLIMK1
SCHEMBL4780457 0.86 ROCK1 (0.45) ROCK1ROCK2AKT1GSK3BLIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716320-B2 Antibacteriall heterocyclic ureas REPLIDYNE, INC. (US) 2014-05-06 US claimed
US-20080207703-A1 Antibacterial heterocyclic ureas REPLIDYNE, INC. (US) 2008-08-28 US claimed
WO-2008011191-A1 ANTIBACTERIAL HETEROCYCLIC UREAS REPLIDYNE, INC. (US) 2008-01-24 WO claimed
US-8716320-B2 Antibacteriall heterocyclic ureas REPLIDYNE, INC. (US) 2014-05-06 US disclosed
US-20080207703-A1 Antibacterial heterocyclic ureas REPLIDYNE, INC. (US) 2008-08-28 US disclosed
WO-2008011191-A1 ANTIBACTERIAL HETEROCYCLIC UREAS REPLIDYNE, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207703-A1 Antibacterial heterocyclic ureas UMPS, UROD, UGP2 ROCK1 4331/4885ROCK2 4405/4885AKT1 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.